Camilla Wendt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Camilla Wendt has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hanne Frøkiær
Department of Veterinary and Animal Sciences University of Copenhagen Frederiksberg Denmark
1 shared publication - Helle W Sørensen
Bioneer A/S, DK-2970 Hørsholm, Denmark
1 shared publication - Jacob Glenting
Bioneer A/S, DK-2970 Hørsholm, Denmark
1 shared publication - Kentaro Kato
Department of Eco-Epidemiology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Nagasaki, Japan
1 shared publication - Lars K. Poulsen
Allergy Clinic, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark
1 shared publication - Søren M. Madsen
Bioneer A/S, Hørsholm, Denmark
1 shared publication
Latest Publications
- Open Access
- 1 January 2007
- Published by Springer Nature in Microbial Cell Factories
- Vol. 6 (1) , 28
Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis
Natural allergen sources can supply large quantities of authentic allergen mixtures for use as immunotherapeutics. However, such extracts are complex, difficult to define, vary from batch to batch, which may lead to unpredictable efficacy and/or unacceptable levels of side effects. The use of recombinant expression systems for allergen production can alleviate some of these issues. Several allergens have been tested in high-level expression systems and in most cases show immunereactivity comparable to their natural counterparts. The gram positive lactic acid bacterium Lactococcus lactis is an attractive microorganism for use in the production of protein therapeutics. L. lactis is considered food grade, free of endotoxins, and is able to secrete the heterologous product together with few other native proteins. Hypersensitivity to peanut represents a serious allergic problem. Some of the major allergens in peanut have been described. However, for therapeutic usage more information about the individual allergenic components is needed. In this paper we report recombinant production of the Ara h 2 peanut allergen using L. lactis.
- 1 January 2007
- Published by Springer Nature in Microbial Cell Factories
- Vol. 6 (1) , 28
Open AccessProduction of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis
Natural allergen sources can supply large quantities of authentic allergen mixtures for use as immunotherapeutics. However, such extracts are complex, difficult to define, vary from batch to batch, which may lead to unpredictable efficacy and/or unacceptable levels of side effects. The use of recombinant expression systems for allergen production can alleviate some of these issues. Several allergens have been tested in high-level expression systems and in most cases show immunereactivity comparable to their natural counterparts. The gram positive lactic acid bacterium Lactococcus lactis is an attractive microorganism for use in the production of protein therapeutics. L. lactis is considered food grade, free of endotoxins, and is able to secrete the heterologous product together with few other native proteins. Hypersensitivity to peanut represents a serious allergic problem. Some of the major allergens in peanut have been described. However, for therapeutic usage more information about the individual allergenic components is needed. In this paper we report recombinant production of the Ara h 2 peanut allergen using L. lactis.